Literature DB >> 18594009

Honokiol suppresses survival signals mediated by Ras-dependent phospholipase D activity in human cancer cells.

Avalon Garcia1, Yang Zheng, Chen Zhao, Alfredo Toschi, Judy Fan, Natalie Shraibman, H Alex Brown, Dafna Bar-Sagi, David A Foster, Jack L Arbiser.   

Abstract

PURPOSE: Elevated phospholipase D (PLD) activity provides a survival signal in several human cancer cell lines and suppresses apoptosis when cells are subjected to the stress of serum withdrawal. Thus, targeting PLD survival signals has potential to suppress survival in cancer cells that depend on PLD for survival. Honokiol is a compound that suppresses tumor growth in mouse models. The purpose of this study was to investigate the effect of honokiol on PLD survival signals and the Ras dependence of these signals. EXPERIMENTAL
DESIGN: The effect of honokiol upon PLD activity was examined in human cancer cell lines where PLD activity provides a survival signal. The dependence of PLD survival signals on Ras was investigated, as was the effect of honokiol on Ras activation.
RESULTS: We report here that honokiol suppresses PLD activity in human cancer cells where PLD has been shown to suppress apoptosis. PLD activity is commonly elevated in response to the stress of serum withdrawal, and, importantly, the stress-induced increase in PLD activity is selectively suppressed by honokiol. The stress-induced increase in PLD activity was accompanied by increased Ras activation, and the stress-induced increase in PLD activity in MDA-MB-231 breast cancer cells was dependent on a Ras. The PLD activity was also dependent on the GTPases RalA and ADP ribosylation factor. Importantly, honokiol suppressed Ras activation.
CONCLUSION: The data provided here indicate that honokiol may be a valuable therapeutic reagent for targeting a large number of human cancers that depend on Ras and PLD for their survival.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18594009      PMCID: PMC2759181          DOI: 10.1158/1078-0432.CCR-08-0102

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  49 in total

Review 1.  Will mTOR inhibitors make it as cancer drugs?

Authors:  Charles L Sawyers
Journal:  Cancer Cell       Date:  2003-11       Impact factor: 31.743

2.  T24 human bladder carcinoma oncogene is an activated form of the normal human homologue of BALB- and Harvey-MSV transforming genes.

Authors:  E Santos; S R Tronick; S A Aaronson; S Pulciani; M Barbacid
Journal:  Nature       Date:  1982-07-22       Impact factor: 49.962

3.  Antimicrobial activity of phenolic constituents of Magnolia grandiflora L.

Authors:  A M Clark; F S El-Feraly; W S Li
Journal:  J Pharm Sci       Date:  1981-08       Impact factor: 3.534

4.  Activation of the T24 bladder carcinoma transforming gene is linked to a single amino acid change.

Authors:  E Taparowsky; Y Suard; O Fasano; K Shimizu; M Goldfarb; M Wigler
Journal:  Nature       Date:  1982-12-23       Impact factor: 49.962

Review 5.  Phospholipase D in cell proliferation and cancer.

Authors:  David A Foster; Lizhong Xu
Journal:  Mol Cancer Res       Date:  2003-09       Impact factor: 5.852

6.  Phospholipase D elevates the level of MDM2 and suppresses DNA damage-induced increases in p53.

Authors:  Li Hui; Tarek Abbas; Rafal M Pielak; Troy Joseph; Jill Bargonetti; David A Foster
Journal:  Mol Cell Biol       Date:  2004-07       Impact factor: 4.272

7.  Phospholipase D confers rapamycin resistance in human breast cancer cells.

Authors:  Yuhong Chen; Yang Zheng; David A Foster
Journal:  Oncogene       Date:  2003-06-19       Impact factor: 9.867

8.  Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein.

Authors:  Keiichi Kondo; Jeff Klco; Eijiro Nakamura; Mirna Lechpammer; William G Kaelin
Journal:  Cancer Cell       Date:  2002-04       Impact factor: 31.743

9.  Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth.

Authors:  Keiichi Kondo; William Y Kim; Mirna Lechpammer; William G Kaelin
Journal:  PLoS Biol       Date:  2003-12-22       Impact factor: 8.029

10.  Dual blockade of EGFR and ERK1/2 phosphorylation potentiates growth inhibition of breast cancer cells.

Authors:  D C Lev; L S Kim; V Melnikova; M Ruiz; H N Ananthaswamy; J E Price
Journal:  Br J Cancer       Date:  2004-08-16       Impact factor: 7.640

View more
  40 in total

1.  Design, synthesis, and biological evaluation of halogenated N-(2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)ethyl)benzamides: discovery of an isoform-selective small molecule phospholipase D2 inhibitor.

Authors:  Robert R Lavieri; Sarah A Scott; Paige E Selvy; Kwangho Kim; Satyawan Jadhav; Ryan D Morrison; J Scott Daniels; H Alex Brown; Craig W Lindsley
Journal:  J Med Chem       Date:  2010-09-23       Impact factor: 7.446

2.  Honokiol inhibits gastric tumourigenesis by activation of 15-lipoxygenase-1 and consequent inhibition of peroxisome proliferator-activated receptor-gamma and COX-2-dependent signals.

Authors:  Shing Hwa Liu; Chin Chang Shen; Yu Chiao Yi; Jaw Ji Tsai; Chih Chien Wang; Ju Ting Chueh; Keh Liang Lin; Tso Ching Lee; Hung Chuan Pan; Meei Ling Sheu
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

Review 3.  Phosphatidic acid signaling to mTOR: signals for the survival of human cancer cells.

Authors:  David A Foster
Journal:  Biochim Biophys Acta       Date:  2009-03-02

4.  Regulation of G1 Cell Cycle Progression: Distinguishing the Restriction Point from a Nutrient-Sensing Cell Growth Checkpoint(s).

Authors:  David A Foster; Paige Yellen; Limei Xu; Mahesh Saqcena
Journal:  Genes Cancer       Date:  2010-11

Review 5.  Phospholipase D: enzymology, functionality, and chemical modulation.

Authors:  Paige E Selvy; Robert R Lavieri; Craig W Lindsley; H Alex Brown
Journal:  Chem Rev       Date:  2011-09-22       Impact factor: 60.622

Review 6.  Targeting phospholipase D with small-molecule inhibitors as a potential therapeutic approach for cancer metastasis.

Authors:  Wenjuan Su; Qin Chen; Michael A Frohman
Journal:  Future Oncol       Date:  2009-11       Impact factor: 3.404

Review 7.  Translating cyclooxygenase signaling in patch heterozygote mice into a randomized clinical trial in basal cell carcinoma.

Authors:  Jack L Arbiser
Journal:  Cancer Prev Res (Phila)       Date:  2010-01

8.  Different redox states in malignant and nonmalignant esophageal epithelial cells and differential cytotoxic responses to bile acid and honokiol.

Authors:  Gang Chen; Julie Izzo; Yusuke Demizu; Feng Wang; Sushovan Guha; Xifeng Wu; Mein-Chie Hung; Jaffer A Ajani; Peng Huang
Journal:  Antioxid Redox Signal       Date:  2009-05       Impact factor: 8.401

Review 9.  Phospholipase D and the maintenance of phosphatidic acid levels for regulation of mammalian target of rapamycin (mTOR).

Authors:  David A Foster; Darin Salloum; Deepak Menon; Maria A Frias
Journal:  J Biol Chem       Date:  2014-07-02       Impact factor: 5.157

Review 10.  Cellular and physiological roles for phospholipase D1 in cancer.

Authors:  Yi Zhang; Michael A Frohman
Journal:  J Biol Chem       Date:  2014-07-02       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.